This medicine is commonly used to address certain bacterial infections across therapeutic domains. It may be part of symptomatic management in conditions where symptoms may intensify temporarily, and contributes to easing the overall symptom load. It helps address groups of symptoms that may become intense or disruptive in conditions such as community-acquired pneumonia, acute sinusitis, pharyngitis, skin infections, and specialized regimens for H. pylori eradication.

This medicine is applied when appropriate as a relevant option when sensitivities may restrict the use of other antibiotics. It is relevant in contexts marked by increased discomfort. It supports the patient during difficult episodes by easing distress and provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Support for Systemic Manifestations Clarithromycin is commonly used to help with symptoms related to systemic imbalance, such as fever and malaise.

---

Regulatory References

1. NIH MedlinePlus overview of Clarithromycin

Official Eligibility and Contraindications for Clarithromycin

Regulatory documentation strictly defines which populations are eligible to use Clarithromycin (Клацид).

Use is Contraindicated (Must Not Use)

Population/Condition
Individuals with known hypersensitivity to Clarithromycin, Erythromycin, or any macrolide antibacterial drug.
Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior macrolide use.
Patients with known QT prolongation or ventricular cardiac arrhythmia (including Torsades de Pointes).
Patients with severe hepatic failure combined with renal impairment or uncorrected hypokalaemia or hypomagnesaemia.

Age and Conditional Use

Clarithromycin film-coated tablets are not recommended for children younger than 12 years; the oral suspension is the established form for pediatric patients 6 months to 12 years. Use in older adults requires consideration of potential renal impairment. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) are only eligible with a mandated dosage reduction.

Pregnancy and Lactation Status

Use is not recommended during pregnancy, especially the first trimester. Due to excretion into breast milk, nursing mothers are advised to discontinue nursing during treatment.

Interactions with other medicines and products

Clarithromycin interacts with many medicinal products due to its documented status as a strong inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. This pharmacokinetic mechanism often reduces the clearance of co-administered drugs, leading to increased systemic exposure.

---

Formal Contraindicated Combinations

Regulatory labels strictly prohibit co-administration with certain drugs due to high risk:

• Pimozide, Cisapride, and Astemizole are contraindicated because of the risk of QT prolongation and potentially fatal cardiac arrhythmias.
• Lovastatin and Simvastatin are prohibited due to a substantially increased risk of myopathy, including rhabdomyolysis.
• Ergot Alkaloids (Ergotamine, Dihydroergotamine) are prohibited due to the risk of acute ergot toxicity, including vasospasm.
• Lurasidone and Oral Midazolam are also formally prohibited.

---

Additional Interaction Constraints

• Co-administration with Colchicine is strictly contraindicated in patients with underlying renal or hepatic impairment.
• Other Statins (e.g., Atorvastatin, Rosuvastatin) require dose adjustment or the use of the lowest registered dose.
• Oral Anticoagulants (e.g., Warfarin) may have potentiated effects, necessitating strict monitoring of coagulation parameters.
• The extended-release tablet formulation must be taken with food, a specific administration-timing requirement noted in the prescribing information.

How Клацид (Clarithromycin) Works

Клацид (Clarithromycin) functions by selectively disrupting the core genetic translation pathway within susceptible bacteria. Its action begins with binding to a site on the 50S ribosomal subunit, specifically the 23S ribosomal RNA ( rRNA) within the peptidyl transferase center. This binding acts as a steric blockade, physically stopping the nascent polypeptide chain from growing within the ribosomal exit tunnel.

This immediate halt to protein synthesis interrupts the entire bacterial growth cascade. By depriving the pathogen of essential functional and structural proteins, the drug rapidly shifts the microbial population into a non-proliferating (bacteriostatic) state. This physiological consequence restricts the overall population of the pathogen, establishing a state where the host's immune system can clear the non-proliferating microbial cells. The mechanism exhibits high structural selectivity, targeting bacterial 70S ribosomes while avoiding human 80S ribosomes. Mechanistic constraints include bacterial efflux pumps and target site modification (e.g., 23S rRNA methylation) that reduce drug affinity.

Administration and Official Use of Клацид (Clarithromycin)

Clarithromycin is administered for systemic use through two principal pathways: oral (using film-coated tablets, extended-release tablets, or oral suspension) and intravenous (IV) infusion. The choice of route and pharmaceutical form is determined by the specific regimen requirements and patient status. The oral suspension form is recommended for pediatric patients, with dosing calculated on a weight-based schedule, typically 7.5 mg/kg every 12 hours.

Dosing and Frequency

Standard dosing for immediate-release (IR) formulations typically ranges from 250 mg to 500 mg, administered every 12 hours. The extended-release (ER) tablets are typically prescribed as 1000 mg and are taken once daily. The intravenous formulation is administered as 500 mg every 12 hours. Dosage requires adjustment for patients with severe renal impairment (creatinine clearance less than 30 mL/min), necessitating a reduction of the total daily dose by one-half.

Procedural Rules and Duration

Specific administration constraints govern the use of certain forms. Extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed. This form must also be taken with food, while immediate-release tablets and suspensions may be taken independently of meals. Intravenous administration requires the drug to be diluted and administered as a slow infusion over a period of at least 60 minutes. Treatment duration typically ranges from 6 to 14 days, with some specific streptococcal infections requiring a minimum course of 10 days. If a dose is missed, it should be taken as soon as possible, but double doses must not be taken to compensate.

Recent Clinical Evidence Overview

Clinical studies involving the antibiotic clarithromycin have focused on characterizing its use in treating bacterial infections across various body systems, particularly those of the respiratory tract and for the eradication of H. pylori associated with ulcers.

Study Activity and Findings

Clarithromycin belongs to the macrolide class of antibiotics. Its activity is primarily characterized by the prevention of bacterial protein synthesis. Studies examining its use in patients typically evaluate its effect against common pathogens, including Streptococcus pneumoniae and certain atypical organisms.

Area of Research	Key Study Findings (Descriptive)
Upper Respiratory Infections (URTIs)	Randomized trials suggest clinical outcomes for clarithromycin are generally comparable to those of other common antibiotics (e.g., penicillins) for conditions like streptococcal pharyngitis and acute sinusitis.
Combination Therapy	Research indicates that using clarithromycin in combination with acid-suppressing agents is a key regimen studied for the successful eradication of H. pylori bacteria.

Cardiovascular Safety Considerations

Specific attention has been given to the cardiovascular profile of macrolides. One major long-term, placebo-controlled clinical trial, the CLARICOR trial, observed an unexpected increase in all-cause death among patients with stable coronary heart disease who received a short course of clarithromycin.

Regulatory agencies advise caution when prescribing clarithromycin to patients with heart disease, and prescribers should weigh the potential benefits against the risk profile. Further research is ongoing to fully understand and characterize this long-term observation in different patient populations.

Common questions about Клацид (FAQ)

Q: Does it make you sleepy?

Official product information states that drowsiness (somnolence) and dizziness are commonly reported adverse effects of this medicine. Regulatory documents include a warning that patients may experience impaired ability and recommend caution when performing activities like driving or operating machinery until they know how the medicine affects them.

---

Q: Is it safe long-term?

Safety data from long-term, open-label studies have described that the medicine was generally seen to be tolerated for periods up to several years at certain dosages. However, for specific conditions like peripheral neuropathic pain, regulatory studies supporting efficacy and safety were not examined for treatment periods extending longer than five months, meaning the regulatory basis for long-term use may vary by indication.

---

Q: Is it safe for children 2 years old?

The medicine is officially indicated for use in pediatric patients with epilepsy starting from specific ages, such as 3 years or 6 years and older, depending on the jurisdiction and specific product label. The medicine is not indicated for use in children under these stated age limits, as the official regulatory labels and clinical studies pertain to older age groups only.

---

Q: How should I store this medicine?

Regulatory information advises storing the medicine at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Storage directions also state that the container must be kept tightly closed and protected from moisture.

Clarithromycin (Клацид) must be stored and handled according to specific rules for each formulation to maintain stability.

Storage Requirements

Formulation	Required Conditions	Stability/Shelf-Life
Tablets / Granules	Store at controlled room temperature (20 C to 25 C); protect from moisture and keep in the original container.	Stable until expiration date.
Reconstituted Suspension	Store between 15 C and 30 C. Do not refrigerate.	Must be discarded after 14 days.

All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Clarithromycin should not be discarded by flushing it down the toilet or pouring it down a drain. The officially preferred method for disposal is using a community drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (e.g., dirt, kitty litter) and placed in a sealed container before being thrown into the household trash, following regulatory guidelines.